Mogamulizumab conveys antibody‐dependent cell‐mediated cytotoxicity to CCR4‐expressing malignant T cells, but tumor evasion with loss of CCR4 may cause drug resistance.228. This evidence concerns the gene CCR4 and neoplasm.